Roy Herbst

402 total citations
12 papers, 329 citations indexed

About

Roy Herbst is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Roy Herbst has authored 12 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Roy Herbst's work include Lung Cancer Diagnosis and Treatment (4 papers), Lung Cancer Treatments and Mutations (4 papers) and HER2/EGFR in Cancer Research (2 papers). Roy Herbst is often cited by papers focused on Lung Cancer Diagnosis and Treatment (4 papers), Lung Cancer Treatments and Mutations (4 papers) and HER2/EGFR in Cancer Research (2 papers). Roy Herbst collaborates with scholars based in United States. Roy Herbst's co-authors include W. K. Hong, Karen Rose Duszynski, Jeanine M. Genkinger, Anthony J. Alberg, H. Takeuchi, S R Keyes, Gulshan Ara, David Northey, Beverly A. Teicher and Fadlo R. Khuri and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Roy Herbst

12 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roy Herbst United States	7	142	119	89	62	56	12	329
M Roselli Italy	7	115 0.8×	74 0.6×	152 1.7×	208 3.4×	25 0.4×	10	450
R. Del Moral Spain	10	143 1.0×	62 0.5×	211 2.4×	99 1.6×	22 0.4×	18	433
Ieta D’Costa Australia	12	130 0.9×	148 1.2×	80 0.9×	82 1.3×	5 0.1×	24	517
Chan Seok Yoon South Korea	9	170 1.2×	45 0.4×	48 0.5×	18 0.3×	20 0.4×	19	377
Sebastian Zahnreich Germany	10	45 0.3×	94 0.8×	139 1.6×	95 1.5×	9 0.2×	27	277
Larry L. Schenken United States	14	136 1.0×	93 0.8×	89 1.0×	133 2.1×	31 0.6×	34	411
Keith D. Jones Canada	5	125 0.9×	47 0.4×	35 0.4×	22 0.4×	31 0.6×	6	441
C Weiler United States	6	189 1.3×	64 0.5×	135 1.5×	90 1.5×	13 0.2×	8	426
Z. Ballatore Italy	11	306 2.2×	132 1.1×	94 1.1×	38 0.6×	12 0.2×	35	544
Joaquina Martínez-Galán Spain	14	257 1.8×	124 1.0×	236 2.7×	36 0.6×	10 0.2×	36	544

Countries citing papers authored by Roy Herbst

Since Specialization

Citations

This map shows the geographic impact of Roy Herbst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Herbst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Herbst more than expected).

Fields of papers citing papers by Roy Herbst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy Herbst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Herbst. The network helps show where Roy Herbst may publish in the future.

Co-authorship network of co-authors of Roy Herbst

This figure shows the co-authorship network connecting the top 25 collaborators of Roy Herbst. A scholar is included among the top collaborators of Roy Herbst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy Herbst. Roy Herbst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Herbst, Roy, Yi‐Lin Wu, Helen Mann, et al.. (2017). P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection. Journal of Thoracic Oncology. 12(11). S2399–S2400. 1 indexed citations

Warren, Graham, Erica N. Peters, Essie Torres, et al.. (2012). Abstract 648: Tobacco assessment in actively accruing Cooperative Group clinical trials. Cancer Research. 72(8_Supplement). 648–648. 2 indexed citations

Xu, Rui‐Hua, C. Y. Huang, Daniel Branstetter, et al.. (2007). Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. Journal of Clinical Oncology. 25(18_suppl). 3535–3535. 18 indexed citations

Herbst, Roy, Razelle Kurzrock, R. S. Benjamin, et al.. (2004). 151 AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors. European Journal of Cancer Supplements. 2(8). 48–48. 6 indexed citations

Sandler, Alan B., Eric D. Mininberg, Edward Kim, et al.. (2003). O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer. Lung Cancer. 41. S36–S36. 2 indexed citations

Herbst, Roy. (2003). Erlotinib (Tarceva): An update on the clinical trial program. Seminars in Oncology. 30(3). 34–46. 78 indexed citations

Alberg, Anthony J., Roy Herbst, Jeanine M. Genkinger, & Karen Rose Duszynski. (2002). Knowledge, attitudes, and behaviors toward skin cancer in Maryland youths. Journal of Adolescent Health. 31(4). 372–377. 66 indexed citations

Herbst, Roy & W. K. Hong. (2002). IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars in Oncology. 29(5). 18–30. 61 indexed citations

Komaki, Ritsuko, L. Milas, Pamela K. Allen, et al.. (2002). Phase III trial of amifostine with chemoradiation for inoperable non-small cell lung cancer (NSCLC): does amifostine protect cancer cells. International Journal of Radiation Oncology*Biology*Physics. 54(2). 105–105. 1 indexed citations

10.

Herbst, Roy & W. K. Hong. (2002). Introduction. Seminars in Oncology. 29(5). 1–2. 1 indexed citations

11.

Komaki, R., Pamela K. Allen, Zhongxing Liao, et al.. (2002). Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Seminars in Radiation Oncology. 12(1). 46–49. 66 indexed citations

12.

Teicher, Beverly A., Gulshan Ara, Roy Herbst, et al.. (1997). PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.. PubMed. 11(4). 301–11. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact